tavaborole
Trade name: kerydin
Approved
Jul 7, 2014
Tavaborole is a boron-based pharmaceutical agent indicated for the topical treatment of toenail onychomycosis, a fungal infection of the nail and nail bed due to Trichophyton rubrum or Trichophyton mentagrophytes infection. Tavaborole acts by inhibiting an aminoacyl-transfer ribonucleic acid (tRNA) synthetase (AARS) - Leucyl-tRNA synthetase. Leucyl-tRNA synthetase is an essential fungal enzyme required for protein synthesis and for the catalysis of ATP-dependent ligation of L-leucine to tRNA(Leu). Tavaborole’s low molecular weight (approximately half of most antifungals, such as terbinafine and efinaconazole) permits optimal nail plate penetration, superior to that of existing topical antifungal medications. — NCATS
Clinical trial activity
11 trials · 1 clinical orgs · 13 marketing orgs
Earliest trial started Nov 1, 2005 (NCT00679523)
Timeline
2010s
2020s
- Oct 13, 2020
Encube Ethicals Pvt. Ltd. — Marketing Organization
- Oct 13, 2020
Perrigo — Marketing Organization
- Oct 13, 2020
Padagis Us — Marketing Organization
- Oct 21, 2020
Alembic — Marketing Organization
- Nov 25, 2020
Amneal Pharmaceuticals — Marketing Organization
- Feb 3, 2021
Chartwell Pharmaceuticals — Marketing Organization
- Feb 3, 2021
Identirx — Marketing Organization
- Feb 8, 2021
Lupin — Marketing Organization
- Feb 9, 2021
Cipla — Marketing Organization
- May 7, 2021
Taro Pharmaceuticals — Marketing Organization
- May 7, 2021
Sun Pharmaceuticals — Marketing Organization
- Apr 10, 2023
Zydus Discovery DMCC — Marketing Organization
Indications
Approved for
Mechanism of action
- Leucine-tRNA ligaseINHIBITOR
Leucine-tRNA ligase inhibitor
Approval history
- approvedJul 7, 2014
Chemistry & pharmacology
SMILES
OB1OCC2=C1C=CC(F)=C2- Mol. weight
- 151.931 g/mol
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Topical
- Availability
- Prescription Only
Oral
No
Parenteral
No
Topical
Yes
Sources
- WikipediaTavaborole ↗
- NCATSK124A4EUQ3 ↗
- ChEMBLCHEMBL443052 ↗
Also known as
- 5-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole
- 5-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole
- 5-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole
- 5-fluoro-2,1-benzoxaborol-1(3h)-ol
- 5-fluoro-2,1-benzoxaborol-1(3h)-ol
- an2690
- an2690
- an2690
- an2690
- an 2690
- an 2690
- an-2690
- an-2690
- an-2690
- an-2690
- an-2690
- an-2690
- kerydin
- kerydin
- kerydin
- kerydin
- tavaborole
- tavaborole
- tavaborole
- tavaborole
- tavaborole
- tavaborole
- tavaborole
- tavaborole
- tavaborole
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03405818 | Phase 4 | Oct 22, 2015 | Pfizer |
| NCT01302119 | Phase 3 | Feb 1, 2011 | Pfizer |
| NCT01270971 | Phase 3 | Dec 1, 2010 | Pfizer |
| NCT01278394 | Phase 2 | Mar 1, 2007 | Pfizer |
| NCT00679601 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2007 | Pfizer |
| NCT00680095 | Phase 1 | Jan 1, 2007 | Pfizer |
| NCT00680134 | Phase 2 | Jun 1, 2006 | Pfizer |
| NCT00679770 | Phase 2 | Jun 1, 2006 | Pfizer |
| NCT00680160 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2006 | Pfizer |
| NCT00679965 | Phase 2 | Feb 1, 2006 | Pfizer |
| NCT00679523 | Phase 2 | Nov 1, 2005 | Pfizer |
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 11 | 11 | 4 | 2005 |
Marketing (17)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Alembic | For profit | MKTG | Oct 21, 2020 |
| Alembic | For profit | SYN | Oct 21, 2020 |
| Amneal Pharmaceuticals | For profit | MKTG | Nov 25, 2020 |
| Anacor | For profit | NDA | Jul 7, 2014 |
| Anacor | For profit | SYN | Jul 7, 2014 |
| Chartwell Pharmaceuticals | For profit | MKTG | Feb 3, 2021 |
| Cipla | For profit | MKTG | Feb 9, 2021 |
| Encube Ethicals Pvt. Ltd. | For profit | MKTG | Oct 13, 2020 |
| Identirx | For profit | MKTG | Feb 3, 2021 |
| Lupin | For profit | MKTG | Feb 8, 2021 |
| Padagis Us | For profit | MKTG | Oct 13, 2020 |
| Perrigo | For profit | MKTG | Oct 13, 2020 |
| Sun Pharmaceuticals | For profit | MKTG | May 7, 2021 |
| Taro Pharmaceuticals | For profit | SYN | May 7, 2021 |
| Taro Pharmaceuticals | For profit | MKTG | Nov 19, 2019 |
| Taro Pharmaceuticals | For profit | MKTG | May 7, 2021 |
| Zydus Discovery DMCC | For profit | MKTG | Apr 10, 2023 |